4.55
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché JAGX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.67
Aprire:
$4.42
Volume 24 ore:
30,197
Relative Volume:
1.28
Capitalizzazione di mercato:
$2.99M
Reddito:
$10.48M
Utile/perdita netta:
$-37.74M
Rapporto P/E:
-0.2811
EPS:
-16.1846
Flusso di cassa netto:
$-29.03M
1 W Prestazione:
-15.43%
1M Prestazione:
-68.40%
6M Prestazione:
-86.11%
1 anno Prestazione:
-95.91%
Jaguar Health Inc Stock (JAGX) Company Profile
Nome
Jaguar Health Inc
Settore
Industria
Telefono
415-371-8300
Indirizzo
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Confronta JAGX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
JAGX
Jaguar Health Inc
|
4.55 | 2.99M | 10.48M | -37.74M | -29.03M | -16.18 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2021-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
2017-07-11 | Iniziato | Rodman & Renshaw | Buy |
Jaguar Health Inc Borsa (JAGX) Ultime notizie
Jaguar Health outlines key Q2 2025 catalysts for crofelemer programs - MSN
Jaguar Health (NASDAQ: JAGX) Subsidiary Napo Pharmaceuticals and RedHill Biopharma Enter U.S. Co-Promotion Agreement for Mytesi, Napo's FDA-Approved Drug Product - ACCESS Newswire
Jaguar Health completes $3.4 million private placement By Investing.com - Investing.com South Africa
Jaguar Health completes $3.4 million private placement - Investing.com India
Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules - ACCESS Newswire
Jaguar Health CEO Leads $3.4M Strategic Investment Ahead of Key 2025 Catalysts - Stock Titan
Jaguar Health, Inc. (NASDAQ:JAGX) Q4 2024 Earnings Call Transcript - Insider Monkey
Jaguar Health Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Jaguar Health Advances Plant-Based Pharmaceuticals - TipRanks
Jaguar Health’s Earnings Call: Growth Amid Challenges - TipRanks
Earnings call transcript: Jaguar Health sees revenue growth in Q4 2024 - Investing.com Canada
JAGX stock plunges to 52-week low, touches $4.9 amid steep decline By Investing.com - Investing.com South Africa
Earnings call transcript: Jaguar Health sees revenue growth in Q4 2024 By Investing.com - Investing.com South Africa
JAGX stock plunges to 52-week low, touches $4.9 amid steep decline - Investing.com
Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023 - ACCESS Newswire
Jaguar Health, Inc. SEC 10-K Report - TradingView
StockNews.com Begins Coverage on Jaguar Health (NASDAQ:JAGX) - Defense World
83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey - Weatherford Democrat
83% of Oncologists Back Revolutionary Non-Antibiotic Treatment for Dogs with Cancer - Stock Titan
Jaguar Health at Emerging Growth Virtual Conference: Strategic Catalysts Ahead - Investing.com
Jaguar Health CEO, board members and investors invest in $3.448M bridge financing - MSN
Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study - ACCESS Newswire
Mytesi Shows Promising Results in Breast Cancer: FDA to Review Game-Changing Phase 3 Data - Stock Titan
Jaguar Health secures $3.448 million in convertible notes By Investing.com - Investing.com South Africa
Sector Update: Health Care - MarketScreener
Jaguar Health secures $3.448 million in convertible notes - Investing.com
Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts - galvnews.com
Jaguar Health Executives Invest in $3.5 Million Bridge Financing; Shares Fall - MarketScreener
Jaguar Health Management Backs Company with Personal Investment in $3.4M Financing Deal - Stock Titan
Upcoming Stock Splits This Week (March 24 to March 28) – Stay Invested - The Globe and Mail
JAGX stock touches 52-week low at $0.21 amid sharp annual decline - Investing.com Australia
JAGX stock touches 52-week low at $0.21 amid sharp annual decline By Investing.com - Investing.com South Africa
Biotech Alert: Searches spiking for these stocks today - TipRanks
Jaguar Health (NASDAQ:JAGX) Now Covered by StockNews.com - Defense World
Jaguar Health initiates reverse stock split to meet Nasdaq standards By Investing.com - Investing.com Canada
Jaguar Health falls as it announces reverse stock split - MSN
Jaguar Health to Implement 1-for-25 Reverse Stock Split -March 18, 2025 at 09:05 am EDT - Marketscreener.com
Jaguar Animal Health Announces Reverse Stock Split - TipRanks
Jaguar Health initiates reverse stock split to meet Nasdaq standards - Investing.com
Jaguar Health, Inc. Announces Reverse Stock Split - ACCESS Newswire
Jaguar Health's Major 1:25 Reverse Split: Critical Move for Nasdaq Compliance - StockTitan
Jaguar Health’s stock slammed after drug that aims to reduce gastro issues in cancer patients fails to meet trial goals - MSN
Jaguar Animal Health Advances Crofelemer for Rare Diseases - TipRanks
Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders - Jonesboro Sun
Breakthrough: Jaguar Health's Cancer Drug Hits Phase 3 Targets, Rare Disease Trials Advance - Stock Titan
JAGX stock touches 52-week low at $0.48 amid market challenges - Investing.com Australia
JAGX stock touches 52-week low at $0.48 amid market challenges By Investing.com - Investing.com South Africa
Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates - ACCESS Newswire
Jaguar Health Announces Completion of Third-party, Investigator-Initiated Study of Crofelemer, which is Expected to Support Orphan Drug Designation (ODD) for Crofelemer for Congenital Diarrheal Disorders (CDD) - ACCESS Newswire
Jaguar Animal Health Exhibiting at the June 23-25 American College of Veterinary Internal Medicine (ACVIM) Forum as Part of Ongoing Commercial Launch Activities for Canalevia-CA1 - ACCESS Newswire
Jaguar Health Inc Azioni (JAGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):